Holen Sie sich die Stockscreener-App
187.61
2.01%
3.7728
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$183.84
Offen:
$186.16
24-Stunden-Volumen:
428.82K
Relative Volume:
0.34
Marktkapitalisierung:
$27.52B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.31
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+2.12%
1M Leistung:
-2.23%
6M Leistung:
+33.88%
1J Leistung:
+35.54%
1-Tages-Spanne:
$185.54
$190.09
1-Wochen-Bereich:
$180.33
$192.28
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
187.53 | 26.98B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
887.94 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
242.15 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
212.93 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
194.19 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.01 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy - benzinga.com
Biogen high-dose Spinraza approval seen supporting long-term growth - Proactive financial news
US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3% - The Economic Times
Biogen stock maintained at Buy by Jefferies on FDA Spinraza approval - investing.com
BMO reiterates Biogen stock rating on Spinraza approval, trial data - investing.com
Morgan Stanley reiterates Biogen stock Equalweight rating on lupus drug data - investing.com
Global markets live: Eli Lilly, Sysco, Biogen, Apple, Boohoo… - marketscreener.com
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $185 to $215 - Moomoo
US FDA approves higher dose of Biogen's genetic disorder drug - Reuters
Orphan Drugs Market is expected to Hit US$ 486.51 billion by 2032 | - openPR.com
FDA approval for SMA dosing option pulls Biogen stock lower amid weak momentum and heavy selling - Traders Union
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen
Biogen’s second positive Phase II litifilimab trial in CLE - The Pharma Letter
6 FDA Decisions To Watch in Q2 2026 - BioSpace
TD Cowen Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Biogen Inc. $BIIB Stake Lowered by Fluent Financial LLC - MarketBeat
Biogen Inc (LTS:0R1B) Bonds - gurufocus.com
Biogen reports positive Phase 2 results for lupus skin drug - investing.com
New lupus medicine research sends Biogen stock down 3.78% amid near-term bearish technicals - Traders Union
Biogen Reports Positive Phase 2 AMETHYST Study Results for Litifilimab in Treating Cutaneous Lupus Erythematosus - Quiver Quantitative
Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus at AAD 2026 - dermatologytimes.com
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - Biogen
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity - GlobeNewswire Inc.
New Alzheimer’s treatment data release sends Biogen stock down 3.78% - Traders Union
Should Biogen’s ALT-B4 Alzheimer’s Delivery Deal Reshape How BIIB Investors View Its Risk Profile? - simplywall.st
Biogen Stock (BIIB) Opinions on Alteogen Partnership - Quiver Quantitative
Nordea Investment Management AB Trims Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Beats Investor Suit Over Dozens Of Drug Claims - Law360
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Advances Litifilimab Delivery Study, Sharpening Its Autoimmune Launch Strategy - TipRanks
Biogen Hybrozyme Deal Links Subcutaneous Biologics Push With Valuation Gap - simplywall.st
Stableford Capital II LLC Acquires New Shares in Biogen Inc. $BIIB - MarketBeat
Discipline and Rules-Based Execution in BIIB Response - Stock Traders Daily
Dakota Wealth Management Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - GuruFocus
Biotech Stocks Facing FDA Decision In April 2026 - RTTNews
Korea roundup: Alteogen, Celltrion lead biotech deals - BioWorld MedTech
Vanguard disaggregates holdings; reports 0 shares in Biogen (NASDAQ: BIIB) - Stock Titan
Fed Meeting: Is Biogen Inc stock undervalued right nowLong Setup & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Alteogen licenses drug delivery tech to Biogen for $579 million By Investing.com - za.investing.com
SG Americas Securities LLC Has $32.35 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Korea's Alteogen signs $549 M deal with Biogen to develop Hybrozyme™-based subcutaneous biologics - BioSpectrum Asia
Biogen Added To Alteogen’s Long List Of Partners - Citeline News & Insights
Alteogen surges on Biogen SC deal, reclaims No.2 on South Korea’s KOSDAQCHOSUNBIZ - Chosunbiz
Hana Securities backs Alteogen as Biogen SC deal sparks Korea growth hopes - Chosunbiz
Biogen Inc. stock under pressure from Leqembi real-world data and pipeline updates at Nasdaq - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Bank Watch: Is now the right time to enter Biogen IncBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
ALTEOGEN INCBIOGEN HAS THE OPTION TO DEVELOP A THIRD PRODUCT UNDER THE AGREEMENT - Intellectia AI
Spinal Muscular Atrophy Clinical Trial Pipeline Expands as 18+ - openPR.com
Biogen inks licensing pact for injectables (BIIB:NASDAQ) - Seeking Alpha
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.87%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):